Roche’s Vabysmo showcases stronghold across wAMD and DME spaces : GlobalData
The data showcases Vabysmo’s efficacy in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vabysmo
New data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular…
In the Tenaya and Lucerne studies, more than 60 per cent of Vabysmo patients could be treated every four months at two years. This…
FDA approves Roche’s Vabysmo to treat nAMD and DME
Vabysmo is the only injectable eye medicine approved simultaneously in the US for neovascular Age-related Macular Degeneration…